1. Search Result
Search Result
Isoforms Recommended: EP
Results for "

EP 3

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

6

Natural
Products

1

Recombinant Proteins

2

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147226

    Prostaglandin Receptor Neurological Disease Endocrinology
    EP3 antagonist 3 (compound 2) is an orally active, potent and selective EP3 antagonist, with a pKi of 8.3. EP3 antagonist 3 shows excellent pharmacokinetic properties. EP3 antagonist 3 can be used for overactive bladder (OAB) research .
    EP3 antagonist 3
  • HY-10418
    AH 6809
    3 Publications Verification

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    AH 6809 is an antagonist of EP and DP receptor, with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively. AH 6809 has a Ki of 350 nM for mouse EP2 receptor .
    AH 6809
  • HY-P5702

    Bacterial Apoptosis Fungal Infection
    EP3 is an antimicrobial peptide. EP3 has antibacterial and antifungal activities. EP3 inhibits E. gallinarum, P. pyocyanea, A. baumanii, K. terrigena with a MIC value of 12.85 μg/mL. EP3 also shows antitumor activity against cancer cells, and induces cell apoptosis .
    EP3
  • HY-157496

    Prostaglandin Receptor Others
    EP3 antagonist 7 (Compound II) is an EP3 receptor antagonist. EP3 antagonist 7 can be used in the study of itching, pain, dysuria or stress disorders .
    EP3 antagonist 7
  • HY-131664

    Prostaglandin Receptor Others
    EP3 antagonist 2 (Compound Exp 1) is a potent and selective EP3 receptor antagonist. EP3 antagonist 2 has a strong binding affinity for the human EP3 receptor (Ki: 3.3 nM) and significant antagonistic activity (IC50: 30.8 nM, determined by cellular cAMP levels) .
    EP3 antagonist 2
  • HY-153256

    Prostaglandin Receptor Metabolic Disease
    EP3 antagonist 4 (Compound 28) is an EP3 antagonist, with a Ki value of 2 nM for hEP. EP3 antagonist 4 shows low in vivo clearance, high oral AUC, and good bioavailability in the rat full PK studies. EP3 antagonist 4 can be used for research of beta cell dysfunction in diabetes .
    EP3 antagonist 4
  • HY-157494

    Prostaglandin Receptor Others
    EP3 antagonist 5 (Compound 22) is an EP3 receptor antagonist with an IC50 value of 67 nM .
    EP3 antagonist 5
  • HY-157495

    Prostaglandin Receptor Endocrinology
    EP3 antagonist 6 (compound 5) is a potent, orally and selective EP3 receptor antagonist, with an IC50 of 1.9 nM. EP3 antagonist 6 can inhibits PGE2-induced (HY-101952) uterine contraction in pregnant rats .
    EP3 antagonist 6
  • HY-RS02304

    Small Interfering RNA (siRNA) Others

    CDC42EP3 Human Pre-designed siRNA Set A contains three designed siRNAs for CDC42EP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDC42EP3 Human Pre-designed siRNA Set A
    CDC42EP3 Human Pre-designed siRNA Set A
  • HY-118820

    M&B 28767

    Prostaglandin Receptor Inflammation/Immunology
    MB-28767 (M&B 28767) is an EP3 receptor agonist .
    MB-28767
  • HY-118609

    Prostaglandin Receptor Inflammation/Immunology
    EP4 receptor agonist 2 (compound 31) a potent EP4 receptor agonist with an EC50 value of 0.8 nM; Ki values of >100000, 38000, 3.1 nM for EP2, EP3, EP4 respectively .
    EP4 receptor agonist 2
  • HY-15274

    CM9; GW671021

    Prostaglandin Receptor Cancer
    L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has ?micromolar activities at the EP4, EP1 and EP2 receptors with Ki values of 916 nM, >5000 nM and >5000 nM, respectively .
    L-798106
  • HY-106054

    Prostaglandin Receptor Metabolic Disease Inflammation/Immunology
    Nocloprost, a prostaglandin E2 (PGE2) analog, is an orally active EP1- and EP3-receptor agonist. Nocloprost inhibits evoked [ 3H]ACh release. Nocloprost has gastroprotective and ulcer-healing properties. Nocloprost accelerates the healing of chronic gastric ulcerations and enhances mucosal growth in rats .
    Nocloprost
  • HY-19361

    Prostaglandin Receptor Neurological Disease
    L-826266 is a selective and competitive EP3 receptor antagonist. L-826266 can be used for convulsive disorders research .
    L-826266
  • HY-16978
    TG6-10-1
    5+ Cited Publications

    5-HT Receptor Prostaglandin Receptor Neurological Disease Endocrinology
    TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors .
    TG6-10-1
  • HY-B0131A

    Prostaglandin Receptor Cardiovascular Disease
    Alprostadil sodium is a prostaglandin receptor ligand that exhibits Ki values of 36, 10, 1.1, 2.1, and 33 nM for the EP1, EP2, EP3, EP4, and IP receptors in mice, respectively. It promotes vasodilation and inhibits platelet aggregation, making it a useful vasodilator for investigating peripheral vascular disease.
    Alprostadil sodium
  • HY-100448A
    Butaprost
    2 Publications Verification

    Prostaglandin Receptor TGF-beta/Smad Endocrinology
    Butaprost is a selective prostaglandin E receptor (EP2) agonist with an EC50 of 33 nM and a Ki of 2.4 μM for murine EP2 receptor. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost attenuates fibrosis by hampering TGF-β/Smad2 signalling .
    Butaprost
  • HY-108563

    Prostaglandin Receptor Neurological Disease
    SC 51089 is a selective antagonist of prostaglandin E2 EP1 receptor, with Kis of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 exhibits neuroprotective activity .
    SC 51089
  • HY-N6070

    Prostaglandin Receptor Inflammation/Immunology
    Ricinoleic acid (purity≥85%), a hydroxy fatty acid, is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings. Ricinoleic acid is the main active ingredient of Castor oil (HY-107799). Ricinoleic acid is the agonist for prostaglandin EP3 receptor (EP3 receptor) (EC50 in MEG-01 is 0.5 μM), that causes laxative effects and uterine contraction. Ricinoleic acid exhibits antianxiety-like, anti-inflammatory and pro-inflammatory properties .
    Ricinoleic acid (purity≥85%)
  • HY-N6070A

    Prostaglandin Receptor Inflammation/Immunology
    Ricinoleic acid (purity≥99%), a hydroxy fatty acid, is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings. Ricinoleic acid is the main active ingredient of Castor oil (HY-107799). Ricinoleic acid is the agonist for prostaglandin EP3 receptor (EP3 receptor) (EC50 in MEG-01 is 0.5 μM), that causes laxative effects and uterine contraction. Ricinoleic acid exhibits antianxiety-like, anti-inflammatory and pro-inflammatory properties .
    Ricinoleic acid (purity≥99%)
  • HY-137574

    19(R)-Hydroxy PGE1

    Prostaglandin Receptor Others
    19(R)-Hydroxy prostaglandin E1 (19(R)-Hydroxy PGE1), the major prostaglandin in primate semen, is an agonist of EP1 and EP3 receptor subtypes and exhibits contractile activity on smooth muscle preparations .
    19(R)-Hydroxy prostaglandin E1
  • HY-120973

    Prostaglandin Receptor TGF-beta/Smad Endocrinology
    Butaprost free acid is a selective prostaglandin E receptor (EP2) agonist with an EC50 of 33 nM and a Ki of 2.4 μM for murine EP2 receptor. Butaprost free acid is less activity against murine EP1, EP3 and EP4 receptors. Butaprost free acid attenuates fibrosis by hampering TGF-β/Smad2 signalling .
    Butaprost free acid
  • HY-14899
    Taprenepag
    4 Publications Verification

    CP-544326

    Prostaglandin Receptor Endocrinology
    Taprenepag (CP-544326) is a potent and selective prostaglandin EP(2) agonist with IC50s of 10 and 15 nM for human and rat EP2, respectively. Taprenepag shows selectivity for EP2 over other EP receptors (IC50s>3200 nM for EP1, EP3, and EP4) and a panel of 37 G protein-coupled receptors .
    Taprenepag
  • HY-133123

    Prostaglandin Receptor Inflammation/Immunology Cancer
    EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC50s of 6.1 nM and 16.2 nM, respectively. IC50s >10 μM for human EP1, EP2,and EP3 receptors .
    EP4 receptor antagonist 1
  • HY-10797
    CJ-42794
    2 Publications Verification

    CJ-042794

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC50 value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers .
    CJ-42794
  • HY-12184

    Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease
    ONO-AE 248 is a selective EP3 receptor agonist with cardioprotective activity. ONO-AE 248 reduces myocardial infarction size by selectively binding to the EP3α receptor in mice. The cardioprotective effect of ONO-AE 248 is independent of hemodynamic effects. The mechanism of ONO-AE 248 may involve activation of protein kinase C and opening of K(ATP) channels .
    ONO-AE 248
  • HY-108563A
    SC 51089 free base
    1 Publications Verification

    Prostaglandin Receptor Neurological Disease
    SC 51089 free base is a selective antagonist of prostaglandin E2 EP1 receptor, with Kis of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 free base exhibits neuroprotective activity .
    SC 51089 free base
  • HY-B0131
    Prostaglandin E1
    Maximum Cited Publications
    11 Publications Verification

    Alprostadil; PGE1

    Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology Cancer
    Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
    Prostaglandin E1
  • HY-B0131S2

    Alprostadil-d9; PGE1-d9

    Isotope-Labeled Compounds Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology
    Prostaglandin E1-d9 is deuterium labeled Prostaglandin E1.Prostaglandin E1 is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inh
    Prostaglandin E1-d9
  • HY-128686
    KAG-308
    2 Publications Verification

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    KAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a Ki and an EC50 of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor .
    KAG-308
  • HY-N6070AR

    Prostaglandin Receptor Inflammation/Immunology
    Ricinoleic acid (purity≥99%) (Standard) is the analytical standard of Ricinoleic acid (purity≥99%). This product is intended for research and analytical applications. Ricinoleic acid (purity≥99%), a hydroxy fatty acid, is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings. Ricinoleic acid is the main active ingredient of Castor oil (HY-107799). Ricinoleic acid is the agonist for prostaglandin EP3 receptor (EP3 receptor) (EC50 in MEG-01 is 0.5 μM), that causes laxative effects and uterine contraction. Ricinoleic acid exhibits antianxiety-like, anti-inflammatory and pro-inflammatory properties .
    Ricinoleic acid (purity≥99%) (Standard)
  • HY-N6070R

    Prostaglandin Receptor Inflammation/Immunology
    Ricinoleic acid (purity≥85%) (Standard) is the analytical standard of Ricinoleic acid (purity≥85%). This product is intended for research and analytical applications. Ricinoleic acid (purity≥85%), a hydroxy fatty acid, is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings. Ricinoleic acid is the main active ingredient of Castor oil (HY-107799). Ricinoleic acid is the agonist for prostaglandin EP3 receptor (EP3 receptor) (EC50 in MEG-01 is 0.5 μM), that causes laxative effects and uterine contraction. Ricinoleic acid exhibits antianxiety-like, anti-inflammatory and pro-inflammatory properties .
    Ricinoleic acid (purity≥85%) (Standard)
  • HY-18971
    TG4-155
    1 Publications Verification

    Prostaglandin Receptor Neurological Disease Inflammation/Immunology Endocrinology Cancer
    TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a Ki of 9.9 nM . TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1 . TG4-155 has an EP2 Schild KB of 2.4 nM and displays 550-4750-fold selectivity for EP2 over EP1, EP3, EP4 and IP, but only 14-fold selectivity against the DP1 receptor .
    TG4-155
  • HY-19360

    SHB 286; CP-34089; ZK-57671

    Prostaglandin Receptor Cardiovascular Disease Inflammation/Immunology
    Sulprostone (SHB 286) is a potent and selective EP3 receptor agonist. Sulprostone (SHB 286) is a prostaglandin E2 (PGE2) analogue and has antiulcer and nonsteroidal abortifacient effects. Sulprostone has potential for the research of pregnancy termination and hemorrhages during delivery .
    Sulprostone
  • HY-50901
    ONO-AE3-208
    5+ Cited Publications

    AE 3-208

    Prostaglandin Receptor Endocrinology Cancer
    ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer .
    ONO-AE3-208
  • HY-50901A

    AE 3-208 sodium salt

    Prostaglandin Receptor Endocrinology Cancer
    ONO-AE3-208 (sodium salt) is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 (sodium salt) shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 (sodium salt) suppresses cell invasion, migration, and metastasis of prostate cancer .
    ONO-AE3-208 sodium salt
  • HY-B0131S

    Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology
    Prostaglandin E1-d4 is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].
    Prostaglandin E1-d4
  • HY-B0131R

    Alprostadil(Standard); PGE1 (Standard)

    Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology Cancer
    Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
    Prostaglandin E1 (Standard)
  • HY-W007888R

    Endogenous Metabolite Metabolic Disease
    Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
    2-Hydroxy-4-methylbenzaldehyde (Standard)
  • HY-136696

    Prostaglandin Receptor Metabolic Disease
    11-Deoxy-16,16-dimethyl-PGE2, a Prostaglandin E2 analog, is a EP2 and EP3 receptors agonist. 11-Deoxy-16,16-dimethyl-PGE2 protects proximal renal tubular epithelial cells from potent nephrotoxicity-induced cell damage by exerting anti-oxidative stress .
    11-Deoxy-16,16-dimethyl-PGE2
  • HY-128039

    Prostaglandin Receptor Others
    17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production .
    17-Phenyl-ω-trinor-PGE2
  • HY-B0813
    Treprostinil diethanolamine
    1 Publications Verification

    UT-15C

    Prostaglandin Receptor Endocrinology
    Treprostinil (UT-15C) diethanolamine is a potent EP2, DP1 and IP agonist with Ki values of 3.6, 4.4, 32.1, 212, 826, 2505 and 4680 nM for EP2, DP1, IP, EP1, EP4, EP3 and FP, respectively. Treprostinil (UT-15C) diethanolamine increases upregulation of cAMP toward maintaining homeostasis within the vasculature. Treprostinil (UT-15C) diethanolamine can result in vasodilatation of human pulmonary arteries .
    Treprostinil diethanolamine
  • HY-10835
    DG-041
    2 Publications Verification

    Prostaglandin Receptor Cardiovascular Disease
    DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier .
    DG-041
  • HY-B0601
    Tafluprost acid
    1 Publications Verification

    AFP-172

    Prostaglandin Receptor Drug Metabolite Cardiovascular Disease Neurological Disease Endocrinology
    Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma .
    Tafluprost acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: